Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1

Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis

Inclusion Criteria:

• Positive Skin Prick Test reaction to birch pollen
• Positive RAST result to birch pollen
• Positive Provocation Test result to birch pollen

Exclusion Criteria:

• Serious chronic diseases
• Other perennial allergies